Potassium Phosphate/Dibasic — Active Pharmaceutical Ingredient

Potassium Phosphate/Dibasic is an active pharmaceutical ingredient found in 47 FDA-approved drug products. Forms: INJECTABLE, SOLUTION. Routes: INJECTION, INTRAVENOUS.

Drug Ingredients A–Z 4 min read
This content is for informational purposes only. Always consult a healthcare professional.

Potassium Phosphate/Dibasic (47 brand names, 2 dosage forms, 2 routes)

Available dosage forms: INJECTABLE, SOLUTION.

Routes of administration: INJECTION, INTRAVENOUS.

Brand Names

  • AMINOSYN 7% W/ ELECTROLYTES
  • AMINOSYN 8.5% W/ ELECTROLYTES
  • AMINOSYN II 10% W/ ELECTROLYTES
  • AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
  • AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
  • AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER
  • AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
  • AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
  • AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
  • AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
  • AMINOSYN II 7% W/ ELECTROLYTES
  • AMINOSYN II 8.5% W/ ELECTROLYTES
  • CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
  • CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
  • CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
  • CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
  • CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
  • CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
  • CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
  • CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER …and 27 more

Indications and Usage

CLINIMIX E is indicated as a source of calories, protein, and electrolytes for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINIMIX E may be used to treat negative nitrogen balance in patients.

Contraindications

The use of CLINIMIX E is contraindicated in: 1.Neonates (28 days of age or younger) receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone calcium salt precipitation in the neonate’s bloodstream [see Warnings and Precautions (5.2), Use in Specific Populations (8.4)]. 2.Patients with known hypersensitivity to one or more amino acids or dextrose [see Warnings and Precautions (5.3)]. 3.Patients with inborn errors of amino acid metabolism due to risk of severe metabolic and neurologic complications. 4.Patients with pulmonary edema or acidosis due to low cardiac output.

Adverse Reactions

The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information. •Pulmonary embolism due to pulmonary vascular precipitates [see Warnings and Precautions (5.1)] •Death in neonates due to calcium-ceftriaxone precipitates [see Warnings and Precautions (5.2)] •Hypersensitivity reactions [see Warnings and Precautions (5.3)] •Risk of Infections [see Warnings and Precautions (5.4)] •Refeeding syndrome [see Warnings and Precautions (5.5)] •Hyperglycemia or hyperosmolar hyperglycemic state [see Warnings and Precautions (5.6)] •Vein damage and thrombosis [see Warnings and Precautions (5.7)] •Hepatobiliary disorders [see Warnings and Precautions (5.8)] •Parenteral Nutrition Associated Liver Disease (PNALD) [see Warnings and Precautions (5.10)] •Electrolyte imbalance and fluid overload [see Warnings and Precautions (5.11)] The following adverse reactions from voluntary reports or clinical studies have been reported with CLINIMIX E. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. •Diuresis •Extravasation •Glycosuria •Hyperglycemia •Hyperosmolar coma

Overdosage

An increased infusion rate of CLINIMIX E can cause hyperglycemia, hyperosmolality, and adverse effects on water and electrolyte balance [see Warnings and Precautions (5.6, 5.11)]. Severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal. Discontinue infusion and institute appropriate corrective measures in the event of overhydration or solute overload during therapy, with particular attention to respiratory and cardiovascular systems. For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.